Related Experiment Video
Updated: Aug 15, 2026
04:11
Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
An accelerated hepatitis B vaccination schedule for young drug users
1Youth Substance Abuse Service, Victoria.
Australian and New Zealand Journal of Public Health
|October 15, 2005
Summary
An accelerated hepatitis B vaccine (HBV) program achieved a 71% completion rate among young drug users. This indicates that targeted vaccination strategies can overcome barriers in this population.
Area of Science:
- Public Health
- Vaccinology
- Addiction Medicine
Background:
- Hepatitis B virus (HBV) infection poses significant risks to young adults, particularly those who use drugs.
- Low vaccination rates are often observed in vulnerable populations due to access and adherence barriers.
Purpose of the Study:
- To evaluate the completion rates of an accelerated hepatitis B vaccination program.
- To assess the acceptability of this program among young drug users.
Main Methods:
- A three-dose hepatitis B vaccine (HBV) schedule (0, 7, 21 days) was offered free to drug users aged 22 years or younger.
- Vaccinations were administered between January 2001 and May 2002 at youth-focused outreach sites in Melbourne, Australia.
- Health records were audited to determine vaccination completion and preferred settings.
Main Results:
- Ninety young individuals initiated the HBV vaccination course.
- A 71% completion rate for the full three-dose regimen was achieved.
- The majority of participants (53%) preferred receiving vaccinations at drug treatment outreach sites.
Conclusions:
- An accelerated hepatitis B vaccination schedule is feasible and acceptable for young drug users.
- Addressing specific barriers, such as preferred vaccination locations, can enhance program success in this population.
- This study supports the implementation of tailored immunization strategies for hard-to-reach groups.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:15Drug Dosage Regimen: Overview
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...